Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Scribe Therapeutics Inc. (SCTX) had Consolidated Net Income/Loss of $-21.81M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$51.17M |
|
$-21.81M |
|
-- |
|
$51.17M |
|
-- |
|
$51.17M |
|
-- |
|
$51.17M |
|
$51.17M |
|
$51.17M |
|
$-21.81M |
|
|
Consolidated Net Income/Loss |
$-21.81M |
$51.17M |
|
$51.17M |
|
$51.17M |
|
2.43M |
|
2.43M |
|
$-8.98 |
|
$-8.98 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
-42.62% |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|